PPARGC1A and ovarian carcinoma: In addition, PGC1α promoted cisplatin resistance by modulating the HSP70/HK2/VDAC1 signaling pathway, affecting the binding of HK2 to VDAC1, causing alterations in mitochondrial membrane potential, and reducing the apoptosis of ovarian cancer cells.